Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Acyclovir-resistant herpes zoster in human immunodeficiency virus-infectedpatients: Results of foscarnet therapy
Autore:
Breton, G; Fillet, AM; Katlama, C; Bricaire, F; Caumes, E;
Indirizzi:
Grpd,osp Pitie Salpetriere, Serv Malad Infect & Trop, Dept Infect & Trop Me Grp Hosp Pitie Salpetriere Paris France 13 & Trop, Dept Infect & Trop Me Grp Hosp Pitie Salpetriere, Dept Virol, F-75651 Paris, France Grp Hosp Pitie Salpetriere Paris France F-75651 l, F-75651 Paris, France
Titolo Testata:
CLINICAL INFECTIOUS DISEASES
fascicolo: 6, volume: 27, anno: 1998,
pagine: 1525 - 1527
SICI:
1058-4838(199812)27:6<1525:AHZIHI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
AIDS PATIENT; VARICELLA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Caumes, E Grpd,osp Pitie Salpetriere, Serv Malad Infect & Trop, Dept Infect & Trop Me Grp Hosp Pitie Salpetriere 47-83 Blvd Hop Paris France 13 op Me
Citazione:
G. Breton et al., "Acyclovir-resistant herpes zoster in human immunodeficiency virus-infectedpatients: Results of foscarnet therapy", CLIN INF D, 27(6), 1998, pp. 1525-1527

Abstract

We retrospectively studied 18 consecutive cases of acyclovir-resistant tester. All the patients had chronic skin lesions that failed to heal despite treatment with intravenous acyclovir (30 mg/[kg.d]) in 15 cases and oral acyclovir (4 g/d) in three cases for >10 days. The mean CD4(+) cell count was20 x 10(6)/L. The mean number of previous tester episodes was 1.53. Fifteen of the 16 patients evaluable for previous acyclovir treatment had received the drug. Thirteen patients were treated with intravenous foscarnet (200 mg/[kg.d]) for a mean of 17.8 days. Complete healing was observed in 10 (77%) of the 13 treated patients. Zoster relapsed after cessation of foscarnettherapy in five of the 10 responding patients. The median time to relapse was 110 days. Four patients died of varicella-zoster virus-associated visceral complications. These results show that acyclovir-resistant tester has apoor prognosis but responds well to foscarnet therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 10:32:33